Image of Oslo Cancer Cluster Innovation Park

New member: Kaiku Health

In this series, we will be introducing one-by-one the new members that have joined our oncology ecosystem in the last six months. Follow us for a new article next week!

One of our newest members is Kaiku Health, a health data science company that will improve the quality of life for cancer patients.

Kaiku Health is a Finnish start-up founded in 2012 by five software developers that care deeply about health care. This exciting new company combines data science, technology and oncology to deliver new medical devices that will help cancer patients, by managing their symptoms digitally.

We talked to Lauri Sippola, CEO and Co-Founder of Kaiku Health, and Ann-Sofie Andersson-Ward, Clinical Partnership Manager Nordics at Kaiku Health, to find out what the company is all about and why they joined our cluster.

Kaiku Health logo

Could you briefly describe Kaiku Health and the role it is taking in cancer?

“Kaiku Health is a health data science company aiming to improve the quality of life of cancer patients. Our digital health intervention platform is based on patient-reported outcomes and classified as a medical device in cancer care. It supports clinical decision making by screening symptoms and notifying care teams. It also provides personalised support for patients. Kaiku Health has modules for over 25 cancer types across different cancer care pathways and is currently in use in over 40 European cancer clinics and hospitals,” said Ann-Sofie Andersson-Ward, Clinical Partnership Manager Nordics.

Why did Kaiku Health join Oslo Cancer Cluster?

“We consider Oslo Cancer Cluster to be a unique node for collaborations focusing on cancer in Norway. As the cluster has members from all parts of the cancer research and care spectrum, we can jointly accelerate the much-needed developments in cancer care. Vital steps forward can be taken due to the ability to secure buy-in, enabling a joint and sustainable focus thus ensuring a better future for cancer patients,” said Ann-Sofie Andersson-Ward, Clinical Partnership Manager Nordics.

“Our vision at Kaiku Health is to provide personalised digital health interventions for every cancer patient. We can only achieve it by working hard together with our partners – of which Oslo Cancer Cluster is a great example”, adds Lauri Sippola, CEO and Co-Founder of Kaiku Health.

Sign up to our monthly newsletter

Two persons working in front a two laptops.

What’s new in Q3?

Positive results from clinical trials, revenue growth and new clinical collaborations … Read some of the third quarter developments from our members below.

BerGenBio logo

BerGenBio

  • BerGenBio showed results from their clinical trial for patients with non-small cell lung cancer, who have previously been treated with chemotherapy. The results showed they met primary and secondary endpoints.
  • The company presented interim safety data from a Phase Ib/II trial. They are testing their drug bemcentinib in combination with pembrolizumab on melanoma patients. The data shows the combination is well tolerated by patients.
  • The U.S. Food and Drug Administration (FDA) has granted bemcentinib Fast Track Designation. This means they will do an expedited review of the investigational drug. The designation is for the treatment of elderly patients with acute myeloid leukemia (AML), who have relapsed.

Read more in the press release from BerGenBio

Nordic Nanovector logo

Nordic Nanovector

  • Nordic Nanovector raised approximately NOK 243 million in private placement of new shares. This will provide further funds to continue the clinical development of their drug Betalutin, manufacturing and other commercial activities.
  • The company presented new results from a clinical trial, testing their drug Betalutin on patients with non-Hodgkins lymphoma (a type of blood cancer). The median duration of response was 13.6 months for all responders and 32.0 months for complete responders.
  • The company reported 3 out of 3 patient responses in the first patient cohort in one of their clinical trials. The patients were given Betalutin in combination with rituximab to treat 3rd-line relapsed or refractory follicular lymphoma (also a type of blood cancer).

Read more in the press release from Nordic Nanovector

Photocure logo

Photocure

  • Photocure reported a revenue growth of 42% in local currency for the US market.
  • The revenues in the Nordics declined 7% to NOK 9.9 million (NOK 10.6 million) in the third quarter.
  • The company entered into a licensing agreement with Asieris Meditech Co. to commercialize the product Cevira to the global market. Cevira is a non-invasive photodynamic therapy for HPV-related (cervical) diseases.

Read more in the press release from Photocure

 

Targovax logo

Targovax

  • Targovax presented new data from the first part of the clinical trial of their oncolytic virus. The trial has shown clinical responses in three out of nine patients. This treatment targets patients with refractory advanced melanoma (skin cancer).
  • The company announced an expansion of the clinical trial of the oncolytic virus ONCOS-102 in combination with the checkpoint inhibitor Imfinzi. This trial is open for patients with advanced peritoneal malignancies (a rare cancer that develops in the tissue that lines the abdomen).
  • The company publicised that Oslo University Hospital will become a site for the clinical trial of their oncolytic virus ONCOS-102.

Read more in the press release from Targovax

 

Ultimovacs logo

Ultimovacs

  • Ultimovacs presented long-term results from the clinical study of their therapeutic cancer vaccine UV1. The patients have non-small cell lung cancer and the trial has shown a 4-year overall survival rate of 39% (7 of 18 patients are still alive).
  • New data from their prostate cancer trial showed a 5-year overall survival rate of 50% (11 of 22 patients are still alive).
  • A phase II clinical trial for patients with malignant melanoma (skin cancer) is projected to start in the first quarter of 2020.

 

More third quarter reports from our other members are or will be made available on their respective websites.

Image of the front page of the booklet "Cancer in Norway 2018"

New report: Cancer in Norway 2018

Cancer Registry of Norway has released the report Cancer in Norway. These are the main points. 

Since the 1950s, Cancer Registry of Norway has published statistical reports of the cancer incidence in Norway almost annually. The past 14 editions of these reports can be found online on the Cancer Registry’s official report page.

In 2018, 34 190 new cancer cases were reported. In order to understand how cancer changes over time in the population, the Cancer Registry examines rates over five-year periods.

Differences between men and women

18 321 men were diagnosed with cancer in 2018.

These are the most common cancer types among men:

  • Prostate cancer, 27,9%
  • Lung cancer, 9,3%
  • Colon cancer, 7,9%
  • Cancer in the urinary tract, 6,9%
  • Skin cancer, non-melanoma, 6,1%

In men, the rates for all cancers combined have been stable. Rates for prostate and lung cancer are decreasing, and so are the rates for rectum cancer, while the trend for colon cancer points slightly upwards.

15 869 women were diagnosed with cancer in 2018.

These are the most common cancer types among women:

  • Breast cancer, 22,3%
  • Colon cancer, 10,1%
  • Lung cancer, 10,0%
  • Melanoma, 6,8%
  • Skin cancer, non-melanoma, 6,4%

There has been a 5,6% increase in the rates among women from the previous five-year period to the most recent one. This reflects increased rates of breast, colon, lung and skin cancer.

Cancer rates by immigrant group

This year the report Cancer in Norway presents cancer rates by immigrant group for the first time.

At the beginning of 2019 immigrants represented 14,3% of the Norwegian population. According to Statistics Norway, about 48% of the immigrants are from Europe, 14% from Africa and 34% from Asia, leaving another 4% from the rest of the world.

Immigrants from outside Europe tend to have lower cancer rates than people born in Norway, the report shows.

In the report foreword Giske Ursin, Director of Cancer Registry of Norway, writes:

“Cancer is predominantly a disease caused by western lifestyle and environment, and many immigrants bring with them a healthier lifestyle associated with lower cancer rates. We may all profit from learning and adapting to a healthier lifestyle.”

Although long-term trends among immigrants tend to be favourable, there are some noteworthy exceptions, according to the report. Immigrants from countries with high smoking prevalence, such as a number of the Eastern European countries, have higher rates of lung cancer.

Socioeconomic factors also matter

The special issue of the report goes in depth on rates among immigrants and also by socioeconomic factors. These factors also matter, according to Giske Ursin:

“We know that socioeconomic status plays a role for several cancers, and a key question is whether there are independent effects linked to income, education and immigrant status. We therefore examine all three factors. We found that a number of cancers are more common among those who have short education or low income. However, we found that the differences between immigrant groups remain after adjustment for socioeconomic factors.”

This information can be used to reduce cancer risk, according to the Cancer Registry – but one size does not fit all in terms of prevention. Ursin writes:

“We need a more targeted approach if we are to prevent cancer in all population subgroups at higher risk of cancer.”

Read the report

  • Cancer in Norway 2018 – Cancer incidence, mortality, survival and prevalence in Norway is available in a printed version. The report is free of charge, and can be ordered by sending an email to kreftregisteret@kreftregisteret.no
  • Or download the report, in English and Norwegian, from the website of the Cancer Registry of Norway
  • The special issue part about immigrants and socioeconomic factors is only available in Norwegian for the time being

 

Sign up to OCC monthly newsletter

Geir Harstad, CEO of Smartfish,

Smartfish with clinical study results

A new clinical study indicates that medical nutrition can improve overall survival in lung cancer patients. 

Oslo Cancer Cluster member Smartfish AS presented the results from a randomized, double-blinded, placebo-controlled trial in the beginning of September. It evaluated one of the company’s medical nutrition products in patients with non-small-cell lung cancer (the most common type of lung cancer) suffering from cachexia.


Cachexia is a complex wasting syndrome, known to have a negative impact on clinical outcomes in patients with cancer and several other chronic diseases.


It is characterised by an ongoing loss of muscle and weight, that eventually can kill the patient.


The results show that the nutrition has a favorable safety profile and indicate a number of positive effects on clinical outcome, for instance that the patients who received the nutrition experienced numerically fewer adverse events from their chemotherapy treatments than the comparator group.

The clinical study

In the pilot study, lung cancer patients who received the nutrition while being pre-cachectic had a statistically significant higher survival after 12 months from baseline compared to the comparator group. 56 patients from 16 clinical sites in Sweden, Italy, Slovakia and Croatia were randomized to receive either Smartfish’s medical nutrition product or a milk-based isocaloric drink.

“This study shows the potential of Remune as an important enhancer of standard cancer care and clinical data like this helps to build awareness of what targeted medical nutrition can do for patients. We are encouraged to continue our research and development to ensure that the best possible nutrition is delivered to the patients who need it.” Geir Harstad, CEO of Smartfish

The medical nutrition product that was tested is called Remune, and is a juice-based drink produced with a proprietary emulsion technology containing unique high levels of Omega 3 fatty acids, vitamin D and whey protein.

The study was recently published online in the journal Nutrition and Cancer and can be read following this link: “Safety and Tolerability of Targeted Medical Nutrition for Cachexia in Non-Small-Cell Lung Cancer: A Randomized, Double-Blind, Controlled Pilot Trial” .

About Smartfish AS

Smartfish AS is active in the research, development, production and marketing of advanced and clinically documented nutritional drinks within medical nutrition and sports nutrition. All Smartfish products are produced on its proprietary juice-based emulsion technology platform with the marine DHA and EPA fatty acids as important ingredients. Smartfish has a number of ongoing clinical development projects and studies in close collaboration with researchers and institutions both in Norway and internationally. The company was founded in 2001 and is located in Oslo, Norway and Lund, Sweden. Smartfish’s main shareholders are Investinor (Norway) and Industrifonden (Sweden). For more information, visit SmartFish official website.

For more information about the study and the company, please contact Jens Nordahl, VP Sales & Marketing, tel +47 996 299 99.

The company’s press release can be read as a PDF in this link.

 

Sign up to OCC monthly newsletter